|Bid||98.89 x 800|
|Ask||100.13 x 900|
|Day's Range||98.96 - 99.87|
|52 Week Range||81.66 - 100.15|
|Beta (3Y Monthly)||0.53|
|PE Ratio (TTM)||29.27|
|Earnings Date||Aug 20, 2019|
|Forward Dividend & Yield||2.16 (2.18%)|
|1y Target Est||104.29|
DUBLIN, July 10, 2019 -- Medtronic plc (the “Company”) (NYSE:MDT) today announced the pricing terms of the previously announced cash tender offers by its wholly-owned indirect.
DUBLIN, July 10, 2019 -- Medtronic plc (the “Company”) (NYSE:MDT) today announced that, pursuant to the previously announced cash tender offers (collectively, the “Tender.
Medtronic PLC NYSE:MDTView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MDT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MDT. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $4.80 billion over the last one-month into ETFs that hold MDT are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Medtronic plc (MDT) today announced two-year outcomes from the LATERAL clinical trial evaluating the use of its HeartWare™ HVAD™ System in patients who received the system via a less-invasive, thoracotomy implant approach. The HVAD System is a heart pump, called a left ventricular assist device (LVAD), that helps increase the amount of blood that circulates through the body in patients with advanced heart failure. Presented at the ASAIO (American Society for Artificial Internal Organs) 65th Annual Conference, the data showed that after two years of follow up, 95 percent of HVAD patients implanted via thoracotomy were free from disabling stroke (Modified Rankin Score, or mRS, greater than 3).
Boston Scientific CEO Michael Mahoney laid out the long-term strategy for the company late last week, including a plan to launch 75 new cardiac valve, brain stimulation and other products by 2022.
Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.
DUBLIN, July 02, 2019 -- Medtronic plc (the “Company”) (NYSE:MDT) today announced that its wholly-owned subsidiary Medtronic Global Holdings S.C.A. (“Medtronic Luxco”) has.
(Bloomberg Opinion) -- Sellers of euro-denominated corporate bonds had their best fund-raising month for three years in June, topping off their best six months since 2012. Some 210 billion euros ($238 billion) in new company debt was snaffled up by investors between January and June, 21% higher than the same period last year.Conditions are rarely better than this for company borrowers as benchmark sovereign bond yields keep falling and credit spreads (the difference between the interest rate on corporate bonds and the yields on those sovereign benchmarks) tighten. And there’s more good news on the horizon possibly, with the European Central Bank thinking about restarting its corporate bond-buying program to help reboot the euro zone’s floundering economy. Goldman Sachs Group Inc. is one of several banks to forecast a return of the ECB to the company credit market.It’s been a frenzy of issuance in 2019, with the consumer goods giants dominating at more than 40% of the total. So-called “Reverse Yankees,” where U.S. companies issue euro-denominated bonds, have featured prominently as American multinationals take advantage of record low interest rates to fund their euro-area operations. Coca-Cola Co., International Business Machines Corp. and Altria Group Inc. all did substantial deals, with nearly 50 billion euros raised this year from U.S entities. The big issuer was Medtronic Plc, a medical products supplier, which came to the market twice with jumbo deals for a total of 12 billion euros.One other statistic stands out at the turn of Europe’s corporate bond year: Nearly half of the issuance has been in maturities of longer than 10 years. As I’ve written regularly, there’s a desperate hunt for yield and investors prefer to buy long-term debt than settle for negative returns.No wonder there’s little sign of the momentum stopping; July is looking very healthy already with eight company issuers announcing new deals on Monday.The chance of the ECB piling in again merely adds to the sense of expectation. Between June 2016 and December 2018 the euro zone’s central bank amassed 178 billion euros of investment grade euro-denominated corporates (although it avoided buying bank paper). The splurge was long-anticipated and credit spreads tightened in expectation of its arrival. A restart to the program – or even the hope of its return – could trigger a similar tightening this time around. If Goldman’s call is correct, that might happen as early as September. This would suggest a balmy summer indeed for credit spreads.To contact the author of this story: Marcus Ashworth at email@example.comTo contact the editor responsible for this story: James Boxell at firstname.lastname@example.orgThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Marcus Ashworth is a Bloomberg Opinion columnist covering European markets. He spent three decades in the banking industry, most recently as chief markets strategist at Haitong Securities in London.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
Insider Monkey tracks hedge funds, billionaires, and prominent value investors for a very simple reason: their consensus picks generally outperform the market. We aren’t the only research shop broadcasting this fact using a bullhorn. Here is what strategist Ben Snider said in Goldman Sachs’ periodic hedge fund report: “Despite the strong track record of popular […]
Minneapolis-St. Paul International Airport is bringing in a veteran of the high-stepping “Riverdance” show to celebrate the July 1 start of direct service between MSP and Dublin.
Goldman Sachs, Medtronic, Mattel, Facebook, Google and SpaceX are the companies to watch.
Some insulin pumps made by med-tech giant Medtronic are vulnerable to cyberattacks that could let a hacker make dangerous changes to a patient's insulin levels, according to alerts from the company and federal regulators.
Medtronic (MDT) was founded in Minneapolis in 1949 as a medical equipment repair company. It is now the world's largest medical device company, headquartered for tax reasons in Dublin, explains Adam Mayers, editor of Adam Mayers Investing.
Boston Scientific will likely top its own three-year guidance for a 6%-9% compound annual growth rate, analysts said Thursday as the medical technology company expands its heart devices.
Medtronic, the Food and Drug Administration and Homeland Security warned Thursday that potentially thousands of older model Medtronic insulin pumps are susceptible to hackers.
"An unauthorized person with special technical skills and equipment could potentially connect wirelessly to a nearby insulin pump to change settings and control insulin delivery," Medtronic said. Medtronic has identified 4,000 patients who are potentially using insulin pumps that are vulnerable to this issue, the agency said.
DUBLIN, June 25, 2019 -- Medtronic plc (the “Company”) (NYSE:MDT) today announced the upsizing of the previously announced cash tender offer (the “Maximum Tender Offer”) by its.
DUBLIN, June 25, 2019 -- Medtronic plc (NYSE:MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. (“Medtronic Luxco”), has priced an offering.
Medtronic PLC (NYSE: MDT )’s announcement that it is commencing an offer for more than $4 billion in debt securities should help the company manage its tax headwind, according to Morgan Stanley. The Analyst ...